Paper Details

  1. Home
  2. Paper Details

Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial.

Author: AxonA T, ChalmersD M, HawkeyP M, RembackenB J, SnellingA M

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated whether a non-pathogenic strain of E. coli (Nissle 1917) could be as effective as mesalazine in preventing relapses of ulcerative colitis. The study also examined if adding this E. coli strain to standard treatment could increase the chances of remission in patients with active ulcerative colitis.
Paper Details　
Original Abstract of the Article :
Ulcerative colitis has been suggested to be caused by infection and there is circumstantial evidence linking Escherichia coli with the condition. Our aim was to find out whether the administration of a non-pathogenic strain of E. coli (Nissle 1917) was as effective as mesalazine in preventing relaps...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/s0140-6736(98)06343-0

データ提供：米国国立医学図書館（NLM）

Non-Pathogenic Escherichia coli vs. Mesalazine for Ulcerative Colitis: A Randomized Trial

[Ulcerative colitis] is a chronic inflammatory bowel disease affecting the colon. This randomized trial compared the effectiveness of [non-pathogenic Escherichia coli (Nissle 1917)] to [mesalazine], a standard medication for ulcerative colitis, in preventing relapse and achieving remission.

Exploring Alternative Therapies for Ulcerative Colitis

The study investigated the potential of non-pathogenic E. coli as a therapeutic agent for ulcerative colitis, seeking to identify a possible alternative to standard medication. While the study found that Nissle 1917 was as effective as mesalazine in preventing relapse, it did not show a significant increase in remission rates when added to standard therapy.

Expanding Understanding of Ulcerative Colitis Treatment

This research contributes to our understanding of ulcerative colitis treatment, exploring the potential of non-pathogenic bacteria as a therapeutic option. The findings suggest that Nissle 1917 may be a viable alternative for preventing relapse, but further research is needed to assess its effectiveness in achieving remission.

Dr.Camel's Conclusion

Imagine a desert traveler seeking relief from a scorching sun. Just as travelers seek shade and hydration, individuals with ulcerative colitis need effective treatment to manage their condition. This study explores a potential oasis of relief in the form of non-pathogenic E. coli, offering a new perspective on treating this challenging condition.

Date :
  1. Date Completed 1999-09-07
  2. Date Revised 2022-03-31
Further Info :

Pubmed ID

10466665

DOI: Digital Object Identifier

10.1016/s0140-6736(98)06343-0

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.